CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Statement of Cash Flows [Abstract]
Net loss	$ (242,911)	$ (74,324)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	9,089	126,183
Impairment of intangible assets	77,358	0
Provision for bad debt expense	(12)	856
Amortization of premium/discount on purchased securities	(51)	93
Write-down of inventory	4,836	0
Gain on disposal of fixed assets	0	(99)
Non-cash equity-based compensation expense	9,407	11,122
Non-cash IPR&D expense	18,029	0
Amortization of debt discount and debt issuance costs	7,513	7,851
Gains on marketable securities, net	(270)	0
Change in fair value of contingent consideration	(21)	(49,184)
Deferred income taxes	630	42,372
Prepaid transaction costs	0	(3,865)
Changes in operating assets and liabilities:
Accounts receivable, net	(7,825)	(11,265)
Inventories	(3,323)	1,223
Prepaid and other current assets	(5,562)	(756)
Accounts payable and accrued expenses	35,479	27,475
Deferred revenues	(101)	7,329
Other assets and liabilities	1,283	117
Net cash (used in) provided by operating activities	(96,452)	85,128
Cash flows from investing activities:
Proceeds from sales or maturities of marketable securities	46,420	44,038
Purchase of marketable securities	(14,815)	(46,726)
Capital expenditures	(1,907)	(1,553)
Net cash provided by (used in) investing activities	29,698	(4,241)
Cash flows from financing activities:
Payments to settle convertible notes	(21,417)	0
Payments of contingent consideration	(27)	(60)
Payments for repurchases of common stock	(13,730)	0
Proceeds from the issuance of common stock under the ESPP	851	0
Proceeds from the exercise of common stock options	30	1,473
Payments of employee tax withholding related to equity-based compensation	(1,748)	(2,362)
Net cash used in financing activities	(36,041)	(949)
Net (decrease) increase in cash, cash equivalents, and restricted cash	(102,795)	79,938
Cash, cash equivalents, and restricted cash related to discontinued operations	0	(59,714)
Cash, cash equivalents, and restricted cash at beginning of the period	253,751	192,770
Cash, cash equivalents, and restricted cash at end of the period	150,956	212,994
Supplemental data for cash flow information:
Cash paid for taxes	433	4,181
Cash paid for interest	5,467	24,171
Non-cash investing and financing activities:
Settlement of note receivable in connection with Perosphere acquisition	10,000	$ 0
Milestone payment accrued for FDA approval of Vyleesi	$ 60,000